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ischemic stroke: possible consequence of
impaired leukotriene biosynthesis
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Background: Leukotrienes are potent inflammatory mediators, which in a number of studies have been found to
be associated with ischemic stroke pathology: gene variants affecting leukotriene synthesis, including the FLAP
(ALOX5AP) gene, have in human studies shown correlation to stroke incidence, and animal studies have
demonstrated protective properties of various leukotriene-disrupting drugs. However, no study has hitherto
described a significant effect of a genetic manipulation of the leukotriene system on ischemic stroke. Therefore, we
decided to compare the damage from focal cerebral ischemia between wild type and FLAP knockout mice.
Damage was evaluated by infarct staining and a functional test after middle cerebral artery occlusion in 20 wild
type and 20 knockout male mice.
Results: Mortality-adjusted median infarct size was 18.4 (3.2-76.7) mm3 in the knockout group, compared to 72.0
(16.7-174.0) mm3 in the wild type group (p < 0.0005). There was also a tendency of improved functional score in
the knockout group (p = 0.068). Analysis of bone marrow cells confirmed that knockout animals had lost their ability
to form leukotrienes.
Conclusions: Since the local inflammatory reaction after ischemic stroke is known to contribute to the brain tissue
damage, the group difference seen in the current study could be a consequence of a milder inflammatory reaction
in the knockout group. Our results add evidence to the notion that leukotrienes are important in ischemic stroke,
and that blocked leukotriene production ameliorates cerebral damage.
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Ischemic stroke is one of the leading causes of death and
long-term disability in the world. Despite the allocation
of huge research efforts in recent years, treatment
options for ischemic stroke remain few. Therefore,
investigations into the pathophysiological intricacies of
the disease are crucial to provide new drug targets.
Inflammation is a prominent feature of stroke patho-
physiology, and has attracted substantial research inter-
est. The massive cell death in the infarct area triggers an
acute and prolonged inflammatory process in the brain,
characterized by activation of microglia, production of* Correspondence: sven.hammarstrom@liu.se
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reproduction in any medium, provided the orinflammatory cytokines and infiltration of various in-
flammatory cells, including neutrophils, T-cells and
monocytes/macrophages, into the damaged tissue. In-
flammation contributes to tissue damage, and especially
the early inflammatory cell infiltration and cytokine pro-
duction seem to be predominantly deleterious [1].
Mounting evidence indicates that leukotrienes (LTs), a
group of potent inflammatory mediators [2], have an im-
portant role in cerebral ischemia, and that components
involved in the LT cascade may be attractive drug
targets. LTs are formed from arachidonic acid (AA) by
5-lipoxygenase (5-LO) upon immunological or inflam-
matory challenge. 5-LO activating protein (FLAP) is an
integral membrane protein localized to the nuclear enve-
lope and endoplasmic reticulum. Both 5-LO and FLAP
are required for formation of LTA4 from endogenous
AA [3-8], and LTA4, is the precursor of all AA-derivedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tors [10-13] is affected by cerebral ischemia, and the
importance of eicosanoids has been proposed from the
observation that AA concentrations are highest in ische-
mic brain regions most sensitive to stroke [14]. Human
genetic studies have demonstrated a significant correl-
ation between stroke risk and polymorphisms in several
of the LT-associated genes, e.g. ALOX5AP encoding
FLAP [15-17], as well as genes encoding LTC4 synthase
[16,18] and cysteinyl (Cys) LT receptors [16]. Also, a
large Swedish epidemiologic study recently showed that
intake of montelukast, a CysLT1R antagonist, was asso-
ciated with a decreased risk of recurrent stroke [19].
Furthermore, animal studies have demonstrated that
drugs interfering with components of the LT pathway,
such as 5-LO [20-22] and LT receptors [23-28], amelior-
ate cerebral ischemic damage. Effects mediated by both
of the established CysLT receptors, CysLT1R [13,24,26-
28] and CysLT2R [10], appear to be involved in ischemic
brain injury. Furthermore, the proposed CysLT receptor
GPR17 was found to be up-regulated in damaged tissues,
and knockout of the GPR17 gene reduced neuronal in-


































































































Figure 1 Leukotriene formation was blocked in FLAP knockout mice.
animals were incubated with 50 μM AA and 20 μM calcium ionophore A23
methanol and supernatants were analyzed by RP-HPLC as described in Ma
absorbance at 360 nm, was recorded versus time. Retention times in minu
panel: analysis of synthetic LTB4 and LTC4. Middle panel: LTB4 was formed b
(lower panel).The use of genetically modified animals is an import-
ant tool in the elucidation of biological mechanisms.
However, in the case of LT effects on stroke, such stud-
ies remain scarce. The only one we are aware of investi-
gated the effect of disrupting the 5-LO gene in mice, but
no significant effects on focal cerebral ischemia were
seen [31]. Because of the suggested importance of FLAP
in human stroke studies, we decided to investigate the
effect of FLAP gene knockout in a rodent middle cere-
bral artery occlusion (MCAo) model. The hypothesis
was that the decreased LT production in the genetically
modified mice would ameliorate the damage from ische-
mic stroke.
Results
FLAP knockout mice do not produce leukotrienes
LTA4 is an obligatory intermediate in the biosynthesis of
LTB4 and LTC4 [32]. It is unstable and thus difficult to
measure by direct methods. Therefore, we measured its
downstream product LTB4 which is efficiently formed
from LTA4 by the widely expressed enzyme LTA4 hydro-
lase. Bone marrow cells from wild type and knockout









































Bone marrow cells obtained from wild type and FLAP knockout
187 for 20 min at 37°C. Reactions were stopped with ice cold
terials and Methods. The absorbance at 270 nm, corrected for stray
tes are indicated for each component in the chromatograms. Upper
y bone marrow cells from wild type mice, but not from knockout mice
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vents formation of LTC4 [33,34] whereas formation of
LTB4 proceeds normally. RP-HPLC analyses showed that
LTB4 was formed by wild type, but not by FLAP knock-
out, bone marrow cells (Figure 1).
FLAP knockout decreased mortality-adjusted infarct size
In the wild type group, two of the included animals died
within 24 h after MCAo, while no included animals died
in the FLAP knockout group. Mortality-adjusted median
infarct size was 18.4 (3.2-76.7) mm3 in the knockout
group, compared to 72.0 (16.7-174.0) mm3 in the wild
type group (p < 0.0005; Figure 2).
FLAP knockout had no significant effect on mortality-
adjusted tail swing test performance
Before MCAo, the wild type and knockout groups
scored close to the theoretical baseline index of 0.50
(equal number of swings to the left and right), with tail
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Figure 2 Infarct sizes were decreased in FLAP knockout mice. In
terms of mortality-adjusted median infarct size, the knockout
animals were protected from focal cerebral ischemia in comparison
to their wild type counterparts (p < 0.0005). Infarct size is presented
in mm3. The segments of the box plots depict the 10th, 25th, 50th,
75th and 90th percentile. The boxes above the box plots represent
the mortality in the two groups. WT =Wild type group, KO = FLAP
knockout group.(0.40-0.60) and 0.65 (0.53-0.70), respectively. The mice
in both groups were severely affected by the ischemic
stroke, and as much as 91% of the wild type and 60% of
the knockout animals scored maximally (1.00 = 100% of
swings to the right) in the tail swing test, thus decreasing
the test sensitivity. Despite this, a trend of better out-
come, which however did not reach statistical signifi-
cance (p = 0.068), was seen in the knockout group.
Mortality-adjusted median tail swing index (proportion
of right side swings) was 1.00 (1.00-1.00) in the wild type
group, compared to 1.00 (0.90-1.00) in the knockout
group (Figure 3).
Perioperative physiological monitoring
The physiological variables monitored during MCAo
were similar between the two groups, as presented in

























: 2 : 0
Figure 3 Tendency of improved functional outcome in FLAP
knockout mice. No significant effect of the genotype difference
was found in the mortality-adjusted tail swing test, although a trend
of better performance in the knockout group was seen (p = 0.068).
The proportion of right sided swings is plotted on the Y-axis. The
segments of the box plots depict the 10th, 25th, 50th, 75th and 90th
percentile. The boxes above the box plots represent the mortality in
the two groups. WT =Wild type group, KO = FLAP knockout group.
Table 1 Perioperatively monitored physiological variables
Group O2 Saturation [%] Heart rate [bpm] Pulse distention [μm] Breath rate [bpm] Breath distention [μm]
Wild type 94.6 (91.1-97.4) 549.0 (523.9-568.6) 25.9 (18.2-36.3) 53.7 (44.7-76.1) 23.8 (19.0-33.1)
Knockout 95.2 (89.5-96.2) 531.5 (491.3-566.5) 17.7 (13.1-24.2) 57.9 (45.6-67.7) 20.6 (19.0-21.9)
All values are presented as median (1st quartile, 3rd quartile).
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In total, 7/20 (35%) animals in the wild type group and
5/20 (25%) animals in the knockout group were
excluded. All exclusions were due to criterion #1; death
during MCAo (Table 2).
Cerebrovascular anatomy
Cerebrovascular anatomy was analyzed in 10 separate
animals by carbon black perfusion and quantitative
image analysis. The analyzed vessels (right and left
MCA, anterior cerebral artery (ACA), posterior cerebral
artery (PCA) and posterior communicating artery
(Pcom)), were observed in all animals. Neither multiple
T-tests nor two-way ANOVA (with the factors [geno-
type], p = 0.204, and [vessel]) revealed any significant dif-
ferences between knockout and wild type animals
regarding vessel outer diameter (Figure 4, Table 3).
Discussion
Knockout of the FLAP gene was associated with ceased
LT production and amelioration of stroke damage in
terms of mortality-adjusted infarct size. Furthermore,
there was a clear trend of improved mortality-adjusted
functional test performance in the knockout group.
Activation of LT synthesis involves translocation to the
nuclear envelope and endoplasmic reticulum of cytosolic
phospholipase A2 (cPLA2) and of 5-LO from the cytosol
and nuclear matrix. cPLA2 subsequently releases AA
from membrane phospholipids [3,5,35]. FLAP resides at
these locations as an integral membrane protein [3-6,8]
and facilitates the transfer of AA from cPLA2 to 5-LO
[36]. The labile intermediate LTA4, formed by 5-LO, is
converted to LTB4 by LTA4 hydrolase or to LTC4 by
LTC4 synthase. LTC4 is exported from the cell and meta-
bolized to two other cysteinyl (Cys) LTs, LTD4 and LTE4.
Both 5-LO and FLAP are required for LTA4 synthesis
from endogenous AA [7], and both FLAP knockout mice
and 5-LO knockout mice lack detectable LT production
[37]. This was confirmed for the FLAP knockout mice in
the current study by stimulating WT and KO bone mar-
row cells under conditions which allow LTB4 formation,Table 2 Number of animals excluded according to respective
Group Criterion #1: Death before




Knockout 5but not LTC4 formation to occur due to lack of cysteine
in the incubation mixture [33,34]. Thus LTB4 represents
the total production of LTs from LTA4. LTB4 is a potent
chemoattractant, which recruits inflammatory cells to
sites of inflammation [38-40]. It also contributes to
leukocyte accumulation by attenuation of leukocyte
apoptosis [41,42]. CysLTs cause wide-spread plasma
leakage by increasing vascular permeability and attract
subsets of T-cells [43-45]. They also activate dendritic
cells and their cytokine release [46,47] as well as mast
cell cytokine production [48], which may also influence
the inflammatory state. Hence, alterations in the LT
pathway affect the inflammatory response, and such
alterations could in turn have an impact on cerebral
ischemia.
It should be noted, however, that inflammation is not
only an important feature in the specific infarct process,
but also in the pathology of atherosclerosis. As men-
tioned above, several genetic studies on human popula-
tions have linked LT-related genes to altered stroke
incidence [15-18]. Such studies, however, do not confer
firm evidence regarding the mechanisms of the effects.
This emphasizes the importance of animal studies, since
they are sin qua non for investigating biological mechan-
isms. As already mentioned, several reports, using mod-
els similar to those in the current study, have
demonstrated protection against stroke by drugs block-
ing LT effects, such as montelukast [23,24] and pranlu-
kast [27,28], strongly suggesting LT-related effects on
the specific infarct pathophysiology. Experiments using
drugs and those employing genetically modified animals
are important complements to each other. The study
using a 5-LO knockout mouse strain, mentioned above,
showed no effects on infarct size after transient MCAo.
That study, however, only included 6 mice per transient
MCAo group, and with infarct size coefficient of vari-
ation (standard deviation divided by mean value) of
around 42% and α = 0.05, the chance (statistical power)
of detecting for example a 30% difference was 45.1%. In
other words, the study was underpowered in this specific
respect, thus not substantiating negative conclusionscriteria in the two groups
re to insert silicone coated
12 mm into the CCA [n]
Criterion #3: Signs of pathology
prior to MCAo surgery [n]
0 0
0 0
Figure 4 Cerebrovascular anatomy in wild type and knockout mice. No cerebrovascular differences between wild type and knockout
animals were found. Brains from carbon black perfused wild type and FLAP knockout animals are depicted. Anterior cerebral artery (ACA), middle
cerebral artery (MCA), posterior cerebral artery (PCA) and posterior communicating artery (Pcom) are pointed out in the figure.
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the first to show that a genetic distortion of the LT system
ameliorates the detrimental effects of cerebral ischemia.
It should be noted that altered inflammatory response
is not the only possible mechanism for the decreased
infarct volumes in the knockout group in the current
experiment. Even though the cerebrovascular anatomy
was similar between the groups, the lack of leukotriene
production may theoretically have affected the blood
flow to the brain, which in turn could decrease the
infarct size. For example, exogenous LTD4 increases the
blood pressure in rats [49] and the FLAP inhibitor
MK886 ameliorates hypertension in L-NAME treated
rats [50].
It is a well-known problem that MCAo studies often
suffer from high random variability regarding infarct
size, and numerous attempts have been made to address
this [51-54]. The source of this variability can be a con-
sequence of for example inconsistency in the filament
insertion procedure and to subtle, individual variationsTable 3 Vessel outer diameter in the two groups






MCA right 0.14 ± 0.012 0.16 ± 0.031 0.15
MCA left 0.14 ± 0.011 0.14 ± 0.015 0.73
ACA right 0.16 ± 0.041 0.17 ± 0.028 0.84
ACA left 0.17 ± 0.033 0.16 ± 0.031 0.61
PCA right 0.18 ± 0.030 0.18 ± 0.036 0.88
PCA left 0.17 ± 0.017 0.17 ± 0.027 0.63
Pcom right 0.12 ± 0.016 0.15 ± 0.033 0.07
Pcom left 0.13 ± 0.007 0.13 ± 0.022 0.88in cerebral vasculature as well as in peroperative hydra-
tion status and body temperature. In the current study,
efforts to minimize random variability included a strictly
standardized operation procedure performed by one sin-
gle surgeon, peroperative surveillance of physiological
parameters and the use of an inbred mouse strain, min-
imizing inter-individual differences.Strengths and weaknesses of the current study
A frequent problem in animal stroke studies is that mor-
tality is neglected, and not included in the final analysis.
A strength of the current study is that this was
addressed by combining mortality with infarct size and
functional score, respectively, in two mortality-adjusted
non-parametrical models. The advantage of this ap-
proach is that the importance of the extreme outcome
of death is acknowledged. A theoretical drawback is that
if mortality was very high in one of the groups, that fac-
tor itself could contribute with so much group difference
that any other variable combined with the mortality rate
would seem significant. In the current study, with only 2
included cases of death, this was not a concern.
Even though 2,3,5-triphenyltetrazolium chloride (TTC)
staining is a well-used and validated method for infarct
size assessment, other staining procedures could have
provided differentiated information regarding the mode
of cell death. It should be noted that any eventual differ-
ences between the groups regarding mode of cell death
remain undisclosed in the current experimental setup.
Such differences may potentially contribute to explaining
the mechanism of the reduced infarct sizes in the knock-
out group, and merit attention in future studies.
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times were tested with the result that for this specific
mouse type, 120 minutes was needed to ensure a rela-
tively consistent infarction. This however caused quite
high mortality if longer convalescence periods were
adopted, which was why we settled for 24 h even though
longer survival times could be beneficial. Theoretically,
the infarct evolution may merely have been delayed in
the knockout group.
Conclusions and future perspectives
We conclude that disruption of the FLAP gene decreases
mortality-adjusted infarct size following MCAo in mice.
It merits emphasis that we do not draw conclusions
regarding the effects on infarct sizes or mortality in sep-
arate, but regarding a combination of the two, which in
our opinion is more relevant. An interesting avenue for
future research would be to study effects of combina-
tions of genetic modifications and LT inhibiting drugs,
to be able to further elucidate the exact mechanisms
involved. Future studies using the FLAP knockout model
on other kinds of brain inflammation might provide im-




A FLAP-knockout mouse strain [37], generously pro-
vided as frozen embryos by Dr. Beverly H. Koller, was
bred at an animal facility in Linköping, Sweden. The ani-
mals were housed in 12 h/12 h light/dark cycles (lights
on at 7 AM). Food (801730, Special Diets Service, Essex,
England) and tap water were provided ad libitum. The
strain was maintained by breeding against 129SvEv mice
(Taconic, Tornbjerg, Denmark) and 5 generations of
backcrossing were made before the stroke experiments.
All procedures were conducted in accordance with the
National Committee for Animal Research in Sweden
and Principles of Laboratory Animal Care (NIH publica-
tion no. 86–23, revised 1985). The protocol was
approved by the Local Ethics Committee for Animal
Care and Use in Linköping.
Experimental procedures
Forty male mice (age: 126 (94–151) days, weight: 28.4
(27.8-29) g) were used for MCAo. Twenty homozygous
FLAP−/− mice were consecutively selected for the knock-
out group, while 20 consecutively selected FLAP+/+ mice
served as controls. The experimenter responsible for
performing the MCAo and infarct assessments (JOS)
was blinded to the genotype of all mice from the start of
experiments and until after infarct size analyses. The
mice were operated in random order.MCAo was performed using the intraluminal filament
method [55,56]. The mice were anesthetized with iso-
flurane (4.5% for induction, 1.8% for maintenance; Fore-
neW, Abbott Scandinavia AB, Solna, Sweden) in an
oxygen/nitrous oxide 30%/70% mixture, and laid in su-
pine position on a thermostatic heating pad connected
to an anal thermometer (50–7061, Harvard Apparatus,
Holliston, MA, USA). Eye gel (Lubrithal™, VetXX,
Uldum, Denmark) was utilized to protect the eyes dur-
ing anesthesia, and before surgery, animals received
1 mL saline subcutaneously for fluid replenishment. The
throat of the mouse was shaved and washed with Iodo-
pax (Jodopax vetW; Pharmaxim AB, Helsingborg, Swe-
den) prior to incision. During MCAo anesthesia, O2
saturation, heart rate, pulse distention, breath rate and
breath distention were monitored by pulse oximetry
(SLS-MO-00404, MouseOx, Allison Park, PA, USA). A
2 cm midline incision was made over the trachea, and
the left common (CCA), external (ECA) and internal ca-
rotid arteries (ICA) were freed from surrounding tissue.
After ligating (6–0 silk suture, Johnson & Johnson, New
Brunswick, NJ, USA) the left CCA and ECA, a suture
was prepared around the left ICA, and the ICA was tem-
porarily clipped (8 mm artery clip, Rebstock Instruments
Gmbh, Dürbheim, Germany). A small incision was sub-
sequently made in CCA, just proximal to the bifurcation,
and a silicon-coated filament (502756, Doccol, Redlands,
CA, USA) was inserted until a slight resistance indicated
correct placement. The intraluminal filament was
secured by a knot, the wound was closed by sutures, and
the mouse was allowed to wake up. After two hours of
occlusion, the animal was reanesthetized, the filament
withdrawn, and the wound closed anew. Topical lidocain
gel (Xylocain 2%, AstraZeneca AB, Södertälje, Sweden)
was used for postoperative analgesia.
Postoperative care
After surgery, the mice were housed solitarily, without
nesting material, in a heated (25-26°C) environment
until sacrifice 24 h later. Food pellets, soaked in water,
were placed on a Petri dish at the cage floor to promote
eating.
Physiological testing
Before MCAo, and one day postoperatively, the mice
were tested for right-left asymmetry by means of the tail
swing test [57]. The animal was held in the tail above
the cage, and the directions of the first 20 lateral
attempts to reach the experimenter’s hand holding the
tail were recorded. A right-left index was subsequently
calculated by dividing the number of right side swings
by the total number of swings. An index of 0.5 therefore
means that the animal swinged an equal number of
times to the right as to the left.
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The animals were lightly anesthetized in isoflurane 24 h
after MCAo and decapitated in a small animal guillotine.
The brains were dissected, immersed in cold water for
two minutes, and cut in 1 mm slices in a mouse brain
matrix (BSMAS001-1, Zivic Instruments, Pittsburgh, PA,
USA). The slices were soaked in TTC (Sigma-Aldrich,
CAS# 298-96-4) in PBS (pH 7.4) for 15 minutes in a
small Petri dish maintained at 37°C. The slices were
scanned (ScanJet 2c, Hewlett-Packard) and infarct areas
were calculated as described by Goldlust [58], using an
automatic 40% green spectrum threshold (SigmaScan
Pro version 5, Systat Software Inc., San Jose, CA, USA).
When infarct areas in each slice had been established,
the lesion volume was calculated by multiplying the
average infarct area of two adjacent slices with the thick-
ness of the tissue in between, which was then summed
up to a total infarct size. Infarct volume is expressed as
mm3, and corrected for edema with the assumption that
the edema in the infarcted hemisphere is not restricted
to the infarct, but also affects surrounding tissue.
Exclusion criteria
Exclusion criteria were established prior to the start of
the experiments:
1. Death before the end of MCAo surgery
2. Failure to insert silicone coated filament at least
12 mm into the CCA
3. Signs of pathology prior to MCAo surgery
Analysis of cerebrovascular anatomy
For analysis of cerebrovascular anatomy, 5 knockout and
5 control mice were perfused with carbon black ink
(Schribtol, drawing ink for calligraphy, Pelikan,
Hannover, Germany) into the left heart ventricle. The
brain was subsequently dissected, and care was taken
not to damage the vasculature. The ventral aspect of the
brain was photographed (Ixus 85 IS, Canon, Tokyo,
Japan) through an operating microscope. The outer dia-
meters of the right and left MCA, ACA, PCA and Pcom
were measured using Sigmascan.
Analysis of leukotriene production
Bone marrow cells were collected from femurs and tibias
of euthanized knockout (FLAP−/−) and control (FLAP
+/+) mice. Equal numbers of cells were incubated for
20 min at 37°C in PBS containing 50 μM AA and 20 μM
calcium ionophore A23187. Reactions were stopped by
addition of ice-cold methanol. Supernatants were col-
lected, cleared from cell debris, evaporated and the resi-
dues were dissolved in methanol and analyzed by RP-
HPLC using a Poroshell 120 EC-C18 column (particle
size 2.7 μm, internal diameter 3 mm, length 50 mm), a1200 series HPLC, and a model 1290 diode array de-
tector (all from Agilent Technologies). LTs were eluted
using methanol/water 7:3 (v/v) plus 0.1% acetic acid,
adjusted to pH 5.7 by ammonium hydroxide (phase A)
for 3 min followed by a linear gradient up to 30% metha-
nol in phase A for 5 min, and finally a linear gradient up
to 100% methanol for 1 min, all at a flow rate of 0.5 ml
per min.Statistics
For the infarct experiments, an a priori power calcula-
tion based on an expected group difference of 40% and
an expected coefficient of variation of 40%, yielded (1-β)
= 0.869 for n = 20 mice in each group. Mortality after
MCAo was combined with lesion size and tail swing test
performance, respectively, in a non-parametric model in
which death was considered the worst possible outcome.
Wilcoxon’s rank-sum test, with α = 0.05, was used for
these analyses (Systat version 11, Systat Software, Inc.
CA, USA). Infarct and test performance data are pre-
sented as median (1st quartile-3rd quartile) throughout.
Cerebrovascular anatomy was compared by t-tests for
each vessel, and by two-way ANOVA with the factors
[genotype] and [vessel] (SPSS, Version 20, IBM Corpor-
ation, Armonk, NY, USA). For the t-tests, N = 5 in each
group rendered an observed power of 0.816 to discover
a 30% vessel diameter difference between the groups,
given an α = 0.05 (Systat version 11, Systat Software, Inc.
CA, USA). Vessel diameter data are presented as mean
± standard deviation throughout.ARRIVE and STAIR
The experiment design and manuscript conform to the
ARRIVE-guidelines of 2011 [59]. Of the 8 STAIR-criteria
[60], developed for preclinical stroke experiments, 4 (ex-
tensive physiological monitoring, randomization and
blinding, more than one effect measure, [intention to]
publish in a peer-review journal) were fulfilled.
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